D Alsadius1, C Olsson, N Pettersson, S L Tucker, U Wilderäng, G Steineck. 1. Division of Clinical Cancer Epidemiology, Department of Oncology, Institute of Clinical Sciences, Sahlgrenska Academy at University of Gothenburg, 413 45, Gothenburg, Sweden, david.alsadius@oncology.gu.se.
Abstract
PURPOSE: This study was conducted to investigate the association of long-term gastrointestinal and urinary symptoms with perceived fecal or urine body odor after radiation therapy for prostate cancer and its effect on survivors' quality of life. METHODS: We used a study-specific questionnaire to measure the occurrence of long-term gastrointestinal and urinary symptoms, the perception of fecal or urine body odor, and quality of life (QoL) 2 to 14 years after radiation therapy for prostate cancer. The questionnaire was sent to 895 eligible survivors who assessed symptom occurrence and QoL in the previous 6 months. RESULTS: We received a filled-in questionnaire from 874 (89 %) men. For the long-term gastrointestinal symptoms, 11/13 were associated with the perception of fecal body odor. For the long-term urinary symptoms, 11/11 were associated with the perception of urine body odor. Men who perceived fecal or urine body odor had a lower quality of life, a lower physical health, and more frequent feelings of depression compared with those who did perceive such body odor. CONCLUSION: Long-term gastrointestinal and urinary symptoms after prostate irradiation are associated with the perception of fecal or urine body odor leading to a reduced quality of life. IMPLICATIONS FOR CANCER SURVIVORS: Disabling body odor after pelvic irradiation needs to be acknowledged in the clinic. Interventions to prevent long-term symptoms may serve the benefit of avoiding fecal or urine body odor after radiation therapy for prostate cancer.
PURPOSE: This study was conducted to investigate the association of long-term gastrointestinal and urinary symptoms with perceived fecal or urine body odor after radiation therapy for prostate cancer and its effect on survivors' quality of life. METHODS: We used a study-specific questionnaire to measure the occurrence of long-term gastrointestinal and urinary symptoms, the perception of fecal or urine body odor, and quality of life (QoL) 2 to 14 years after radiation therapy for prostate cancer. The questionnaire was sent to 895 eligible survivors who assessed symptom occurrence and QoL in the previous 6 months. RESULTS: We received a filled-in questionnaire from 874 (89 %) men. For the long-term gastrointestinal symptoms, 11/13 were associated with the perception of fecal body odor. For the long-term urinary symptoms, 11/11 were associated with the perception of urine body odor. Men who perceived fecal or urine body odor had a lower quality of life, a lower physical health, and more frequent feelings of depression compared with those who did perceive such body odor. CONCLUSION: Long-term gastrointestinal and urinary symptoms after prostate irradiation are associated with the perception of fecal or urine body odor leading to a reduced quality of life. IMPLICATIONS FOR CANCER SURVIVORS: Disabling body odor after pelvic irradiation needs to be acknowledged in the clinic. Interventions to prevent long-term symptoms may serve the benefit of avoiding fecal or urine body odor after radiation therapy for prostate cancer.
Authors: Gunnar Steineck; Karin Bergmark; Lars Henningsohn; Massoud al-Abany; Paul W Dickman; Asgeir Helgason Journal: Acta Oncol Date: 2002 Impact factor: 4.089
Authors: H Jervoise N Andreyev; Panagiotis Vlavianos; Peter Blake; David Dearnaley; Andrew R Norman; Diana Tait Journal: Int J Radiat Oncol Biol Phys Date: 2005-08-01 Impact factor: 7.038
Authors: Eva Johansson; Gunnar Steineck; Lars Holmberg; Jan-Erik Johansson; Tommy Nyberg; Mirja Ruutu; Anna Bill-Axelson Journal: Lancet Oncol Date: 2011-08-05 Impact factor: 41.316
Authors: Gunnar Steineck; Fred Helgesen; Jan Adolfsson; Paul W Dickman; Jan-Erik Johansson; Bo Johan Norlén; Lars Holmberg Journal: N Engl J Med Date: 2002-09-12 Impact factor: 91.245
Authors: Anders Widmark; Olbjørn Klepp; Arne Solberg; Jan-Erik Damber; Anders Angelsen; Per Fransson; Jo-Asmund Lund; Ilker Tasdemir; Morten Hoyer; Fredrik Wiklund; Sophie D Fosså Journal: Lancet Date: 2008-12-16 Impact factor: 79.321
Authors: Asif Harsolia; Carlos Vargas; Di Yan; Donald Brabbins; David Lockman; Jian Liang; Gary Gustafson; Frank Vicini; Alvaro Martinez; Larry L Kestin Journal: Int J Radiat Oncol Biol Phys Date: 2007-11-15 Impact factor: 7.038
Authors: Rebecca Ahlin; Karin Bergmark; Cecilia Bull; Sravani Devarakonda; Rikard Landberg; Ida Sigvardsson; Fei Sjöberg; Viktor Skokic; Gunnar Steineck; Maria Hedelin Journal: Front Nutr Date: 2021-12-07